Joseph Zakrzewski
Chairman
Mr. Zakrzewski is currently the Chief Executive Officer and Director of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines. Mr. Zakrzewski recently served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 through the first quarter of 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance and business development. His most recent position was Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a global basis. Mr. Zakrzewski received a BS in Chemical Engineering in 1986; an MS in Biochemical Engineering from Drexel University in 1988, and received an MBA in Finance in 1992 from Indiana University. In addition to his role on the Xcellerex board of directors, Mr. Zakrzewski also serves as a member of the Board of Insulet, Arius Research, and DOV Pharmaceutical.
Dominick C. Colangelo
CEO - Promedior, Inc.
Mr. Colangelo joined Promedior in December 2008 with 15 years of
pharmaceutical industry experience, including nearly a decade with Eli Lilly and
Company. During his career, Mr. Colangelo has held a variety of executive
positions of increasing responsibility in finance, product development,
pharmaceutical operations, and corporate business development. During his
tenure at Eli Lilly and Company, Mr. Colangelo held positions as an
international tax attorney in the finance organization and as Director of
Strategy and Business Development for Lilly’s Diabetes and Growth Disorders
Product Group. He also served as a founding Managing Director of Lilly
Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the
State University of New York at Buffalo and a J.D. degree from the Duke
University School of Law.
James W. Broderick, M.D.
General Partner - Morgenthaler Ventures
James Broderick, M.D., is a General Partner at Morgenthaler Ventures and invests
in companies developing innovative biotech and medical device therapeutic
products. He was a co-founder of Promedior. He is also founding CEO of
Innovative Metabolics, and an investor and board member of several other novel
biotech and medical device companies including OncoMed Pharmaceuticals, Bayhill
Therapeutics, Spine Wave, Symphony Medical, and Trellis Bioscience. Previously,
Dr. Broderick served as a director at NexTag.
He opened Morgenthaler's Boston office in 2005 after spending several years in
Silicon Valley. Trained as a physician and an engineer, Dr. Broderick is a
graduate of MIT (Bachelors in Mechanical Engineering) and University of
Massachusetts (Doctor of Medicine). He was a member of the Kauffman Fellows
Program, a two year educational fellowship sponsored by the Kauffman Center for
Entrepreneurial Leadership designed to train future venture capitalists and
leaders of high growth companies. Dr. Broderick had previously worked as a
consultant at Mercer Management Consulting, and as a resident at Duke University
Medical Center.
Amir Nashat, Ph.D.
General Partner - Polaris Venture Partners
Amir Nashat, Ph.D., is a General Partner in the Boston office of Polaris Venture
Partners. He joined Polaris in April 2002 and focuses on investments in the life
sciences.
Prior to joining Polaris, Dr. Nashat completed his Ph.D. as a Hertz Fellow in
Chemical Engineering at the Massachusetts Institute of Technology with a minor
in Biology under the guidance of Dr. Robert Langer. His doctoral research
focused on information flow through neurons, neural implants, and neural tissue
engineering. During his time at M.I.T., he completed an internship in the London
office of Goldman, Sachs & Company, where he worked on interest rate derivative
products.
Dr. Nashat currently represents Polaris as a Director of Athenix Corporation,
eNOS Pharmaceuticals, Hydra Biosciences, Promedior Inc., Pervasis Therapeutics
Inc. (where he was founding President), T2 Biosystems and WaveRx.
Additionally, he is Board Observer to GI Dynamics, and supports Polaris'
Investment in Advion. He currently serves on the Board of the New England
Venture Capital Association, on the Advisory Board of the Simmons School of
Management Entrepreneurship Initiative, and is a Catalyst for the Deshpande
Center for Technological Innovation at M.I.T.
Prior to obtaining his Ph.D. at MIT, Dr. Nashat earned both his M.S. and B.S. in
Materials Science and Mechanical Engineering at the University of California,
Berkeley.
HAROLD (hAL) r. wERNER
General Partner - HealthCare Ventures, LLC
Mr. Werner is a General Partner of HealthCare Ventures. He is a member of the Board of Directors of Aciex, Inc., DecImmune Therapeutics, Innomab, Oriel Therapeutics, Inc., Promedior, Inc., Stemgent, Inc., Tetralogic Pharmaceuticals, Inc., and Xencor, Inc., all private companies. He is also a member of the Board of Directors of MiddleBrook Pharmaceuticals, a public company. Mr. Werner received his MBA from the Harvard Graduate School of Business and his BS and MS degrees from Princeton University.
Geert-Jan Mulder, M.D.
Forbion Capital Partners
Geert-Jan Mulder, General Partner at Forbion Capital Partners (formerly
ABN AMRO Capital Life Sciences.), is an MD and accredited Pharmaceutical
Physician. Before joining the pharmaceutical industry, he gained his clinical
experience at the University Medical Center of Utrecht (UMC) in the field of
Obstetrics and Gynecology. He then joined Searle (now Pfizer) as Medical Adviser
in the field of arthritis and pain (COX-2 technology) and worked on the local
and European positioning of celecoxib. After working at Searle, he joined Byk
Gulden (now Nycomed) where his department was responsible for clinical
development in The Netherlands dealing with the design and execution of numerous
corporate clinical trials in the fields of Gastroenterology, Respiratory (asthma
and COPD), Intensive Care Medicine and Imaging. On corporate level, he served as
a member of the Global Medical Marketing group of the Respiratory franchise.
Besides taking an active role in the Forbion Capital Partners investment
process, he serves on a number of boards and assists portfolio companies in
their clinical development programs and overall strategy.
John H. Friedman
Easton Capital Investment Group
Paul D. Goldenheim, M.D.
Former President - TransForm Pharmaceuticals, Inc.
Dr. Goldenheim is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies. He has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. He also serves on several non-profit boards. Dr. Goldenheim obtained both his A.B. and M.D. degrees from Harvard.